Blog Post
Deal in Review: AbbVie Acquires Cerevel
On December 26th 2023, AbbVie announced that it will acquire Massachusetts based biotech Cerevel Therapeutics for $45.00 per share. The transaction represents an equity value
On December 26th 2023, AbbVie announced that it will acquire Massachusetts based biotech Cerevel Therapeutics for $45.00 per share. The transaction represents an equity value